NasdaqGM - Nasdaq Real Time Price USD

AC Immune SA (ACIU)

Compare
2.7200
-0.0800
(-2.86%)
At close: January 10 at 4:00:02 PM EST
2.7000
-0.02
(-0.74%)
After hours: January 10 at 6:12:54 PM EST
Currency in CHF All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
40,973.0000
14,801.0000
3,935.0000
--
15,431.0000
Operating Expense
78,274.0000
68,425.0000
74,782.0000
79,010.0000
76,691.0000
Operating Income
-37,301.0000
-53,624.0000
-70,847.0000
-79,010.0000
-61,260.0000
Net Non Operating Interest Income Expense
2,469.0000
868.0000
-286.0000
5,904.0000
-106.0000
Other Income Expense
128.0000
-1,467.0000
393.0000
113.0000
-555.0000
Pretax Income
-39,862.0000
-54,223.0000
-70,740.0000
-72,993.0000
-61,921.0000
Tax Provision
1.0000
10.0000
13.0000
3.0000
--
Net Income Common Stockholders
-39,863.0000
-54,233.0000
-70,753.0000
-72,996.0000
-61,921.0000
Diluted NI Available to Com Stockholders
-39,863.0000
-54,233.0000
-70,753.0000
-72,996.0000
-61,921.0000
Basic EPS
-0.40
-0.64
-0.85
-0.97
-0.86
Diluted EPS
-0.40
-0.64
-0.85
-0.97
-0.86
Basic Average Shares
96,380.1900
84,694.6160
83,554.4120
74,951.8330
71,900.2120
Diluted Average Shares
96,380.1900
84,694.6160
83,554.4120
74,951.8330
71,900.2120
Total Operating Income as Reported
-37,301.0000
-53,624.0000
-70,847.0000
-79,010.0000
-61,260.0000
Total Expenses
78,274.0000
68,425.0000
74,782.0000
79,010.0000
76,691.0000
Net Income from Continuing & Discontinued Operation
-39,863.0000
-54,233.0000
-70,753.0000
-72,996.0000
-61,921.0000
Normalized Income
-35,260.5500
-52,912.7000
-71,094.9100
-73,105.6100
-61,366.0000
Interest Income
2,598.0000
1,044.0000
69.0000
6,485.0000
78.0000
Interest Expense
129.0000
176.0000
355.0000
581.0000
184.0000
Net Interest Income
2,469.0000
868.0000
-286.0000
5,904.0000
-106.0000
EBIT
-39,733.0000
-54,047.0000
-70,385.0000
-72,412.0000
-61,737.0000
EBITDA
-37,545.0000
-51,832.0000
-68,026.0000
-70,006.0000
-59,770.0000
Reconciled Depreciation
2,188.0000
2,215.0000
2,359.0000
2,406.0000
1,967.0000
Net Income from Continuing Operation Net Minority Interest
-39,863.0000
-54,233.0000
-70,753.0000
-72,996.0000
-61,921.0000
Total Unusual Items Excluding Goodwill
-5,030.0000
-1,467.0000
393.0000
113.0000
-555.0000
Total Unusual Items
-5,030.0000
-1,467.0000
393.0000
113.0000
-555.0000
Normalized EBITDA
-32,515.0000
-50,365.0000
-68,419.0000
-70,119.0000
-59,215.0000
Tax Rate for Calcs
0.0001
0.0001
0.0001
0.0000
--
Tax Effect of Unusual Items
-427.5500
-146.7000
51.0900
3.3900
--
12/31/2020 - 9/23/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

OBIO Orchestra BioMed Holdings, Inc.
5.47
+1.86%
 
MGTX MeiraGTx Holdings plc
6.20
-2.36%
 
IMRX Immuneering Corporation
2.0700
+3.50%
 
SPRC SciSparc Ltd.
0.8149
+1.03%
 
MURA Mural Oncology plc
3.8900
+6.58%
 
SCPX Scorpius Holdings, Inc.
0.3800
-0.26%
 
MBIO Mustang Bio, Inc.
0.2566
+15.38%
 
BLRX BioLineRx Ltd.
0.1429
+0.21%
 
CTMX CytomX Therapeutics, Inc.
0.8801
-10.45%
 
CERO CERo Therapeutics Holdings, Inc.
2.9600
-20.00%